Twist Bioscience Reports Q2 Loss, Revenue Exceeds Estimates

Twist Bioscience reported a second quarter loss of $0.66 per share, missing analyst expectations, but exceeded revenue forecasts with $92.8 million, reflecting continued growth across all business segments. The company's gross margin improved to 49.6%, approaching its goal of surpassing 50% by the end of fiscal 2025, and adjusted EBITDA losses narrowed, signaling progress toward profitability. Despite these operational improvements, the stock remains down over the past year, underperforming the broader market. Analysts note positive trends in revenue growth, margin enhancement, and geographic diversification, supported by a strong cash position. The company's innovative synthetic DNA platform positions it well for future opportunities in medicine, agriculture, and other sectors. However, continued monitoring of earnings revisions and management's outlook will be important for investors.